|
1
|
Tomlins SA, Rhodes DR, Perner S,
Dhanasekaran SM, Mehra R, Sun XW, Varambally S, Cao X, Tchinda J,
Kuefer R, et al: Recurrent fusion of TMPRSS2 and ETS transcription
factor genes in prostate cancer. Science. 310:644–648. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Perner S, Demichelis F, Beroukhim R,
Schmidt FH, Mosquera JM, Setlur S, Tchinda J, Tomlins SA, Hofer MD,
Pienta KG, et al: TMPRSS2:ERG fusion-associated deletions provide
insight into the heterogeneity of prostate cancer. Cancer Res.
66:8337–8341. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Helgeson BE, Tomlins SA, Shah N, Laxman B,
Cao Q, Prensner JR, Cao X, Singla N, Montie JE, Varambally S, et
al: Characterization of TMPRSS2:ETV5 and SLC45A3:ETV5 gene fusions
in prostate cancer. Cancer Res. 68:73–80. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Kumar-Sinha C, Tomlins SA and Chinnaiyan
AM: Recurrent gene fusions in prostate cancer. Nat Rev Cancer.
8:497–511. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Attard G, Parker C, Eeles RA, Schröder F,
Tomlins SA, Tannock I, DrakeZZC G and de Bono JS: Prostate cancer.
Lancet. 387:70–72. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Barbieri CE, Baca SC, Lawrence MS,
Demichelis F, Blattner M, Theurillat JP, White TA, Stojanov P, Van
Allen E, Stransky N, et al: Exome sequencing identifies recurrent
SPOP, FOXA1 and MED12 mutations in prostate cancer.
Nature Genet. 44:685–689. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Cavanagh H and Rogers KM: The role of
BRCA1 and BRCA2 mutations in prostate, pancreatic and
stomach cancers. Hered Cancer Clin Pract. 1(13): 162015. View Article : Google Scholar
|
|
8
|
Witte JS, Mefford J, Plummer SJ, Liu J,
Cheng I, Klein EA, Rybicki BA and Casey G: HOXB13 mutation
and prostate cancer: Studies of siblings and aggressive disease.
Cancer Epidemiol Biomarkers Prev. 22:675–680. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Miyagi Y, Sasaki T, Fujinami K, Sano J,
Senga Y, Miura T, Kameda Y, Sakuma Y, Nakamura Y, Harada M and
Tsuchiya E: ETS family-associated gene fusions in Japanese
prostate cancer: analysis of 194 radical prostatectomy samples. Mod
Pathol. 23:1492–1498. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Haffner MC, Mosbruger T, Esopi DM, Fedor
H, Heaphy CM, Walker DA, Adejola N, Gürel M, Hicks J, Meeker AK, et
al: Tracking the clonal origin of lethal prostate cancer. J Clin
Invest. 123:4918–4922. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Shoag J, Liu D, Blattner M, Sboner A, Park
K, Deonarine L, Robinson BD, Mosquera JM, Chen Y, Rubin MA and
Barbieri CE: SPOP mutation drives prostate neoplasia without
stabilizing oncogenic transcription factor ERG. J Clin Invest.
128:381–386. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Tamada Y, Imoto S, Araki H, Nagasaki M,
Print C, Charnock-Jones DS and Miyano S: Estimating genome-wide
gene networks using nonparametric Bayesian network models on
massively parallel computers. IEEE/ACM Trans Comput Biol Bioinform.
8:683–697. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Imoto S, Goto T and Miyano S: Estimation
of genetic networks and functional structures between genes by
using Bayesian network and nonparametric regression. Pac Symp
Biocomput. 7:175–186. 2002.
|
|
14
|
Huang J, Wang JK and Sun Y: Molecular
pathology of prostate cancer revealed by next-generation
sequencing: Opportunities for genome-based personalized therapy.
Curr Opin Urol. 23:189–193. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Beltran H, Yelensky R, Frampton GM, Park
K, Downing SR, MacDonald TY, Jarosz M, Lipson D, Tagawa ST, Nanus
DM, et al: Targeted next-generation sequencing of advanced prostate
cancer identifies potential therapeutic targets and disease
heterogeneity. Eur Urol. 63:920–926. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Zhu Y, Ren S, Jing T, Cai X, Liu Y, Wang
F, Zhang W, Shi X, Chen R, Shen J, et al: Clinical utility of a
novel urine-based gene fusion TTTY15-USP9Y in predicting prostate
biopsy outcome. Urol Oncol. 33:384.e9–20. 2015. View Article : Google Scholar
|
|
17
|
St John J, Powell K, Conley-Lacomb MK and
Chinni SR: TMPRSS2-ERG fusion gene expression in prostate tumor
cells and its clinical and biological significance in prostate
cancer progression. J Cancer Sci Ther. 4:94–101. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Rubin MA, Maher CA and Chinnaiyan AM:
Common gene rearrangements in prostate cancer. J Clin Oncol.
29:3659–3668. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Shannon P, Markiel A, Ozier O, Baliga NS,
Wang JT, Ramage D, Amin N, Schwikowski B and Ideker T: Cytoscape: A
software environment for integrated models of biomolecular
interaction networks. Gnome Res. 13:2498–2504. 2003. View Article : Google Scholar
|
|
20
|
Jiao X, Sherman BT, Huang da W, Stephens
R, Baseler MW, Lane HC and Lempicki RA: DAVID-WS: A stateful web
service to facilitate gene/protein list analysis. Bioinformatics.
28:1805–1806. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Supek F, Bošnjak M, Škunca N and Šmuc T:
REVIGO summarizes and visualizes long lists of Gene Ontology terms.
PLoS One. 6:e218002011. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Menzies AM and Long GV: Long, dabrafenib
and trametinib, alone and in combination for BRAF-mutant metastatic
melanoma. Clin Cancer Res. 20:2035–2043. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Shihab HA, Gough J, Cooper DN, Stenson PD,
Barker GL, Edwards KJ, Day IN and Gaunt TR: Predicting the
functional, molecular and phenotypic consequences of amino acid
substitutions using hidden Markov models. Hum Mutat. 34:57–65.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Shihab HA, Gough J, Cooper DN, Day INM and
Gaunt TR: Predicting the functional consequences of
cancer-associated amino acid substitutions. Bioinformatics.
29:1504–1510. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Shihab HA, Gough J, Mort M, Cooper DN, Day
IN and Gaunt TR: Ranking non-synonymous single nucleotide
polymorphisms based on disease concepts. Hum Genom. 8:112014.
View Article : Google Scholar
|
|
26
|
Simões-Correia J, Figueiredo J, Lopes R,
Stricher F, Oliveira C, Serrano L and Seruca R: E-Cadherin
destabilization accounts for the pathogenicity of missense
mutations in hereditary diffuse gastric cancer. PLoS One.
7:e337832012. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Ren S, Peng Z, Mao JH, Yu Y, Yin C, Gao X,
Cui Z, Zhang J, Yi K, Xu W, et al: RNA-seq analysis of prostate
cancer in the Chinese population identifies recurrent gene fusions,
cancer-associated long noncoding RNAs and aberrant alternative
splicings. Cell Res. 22:806–821. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Kumar-Sinha C, Kalyana-Sundaram S and
Chinnaiyan AM: SLC45A3-ELK4 chimera in prostate cancer: Spotlight
on cis-splicing. Cancer Discov. 2:582–585. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Zhang Y, Mao XY, Liu X, Song RR, Berney D,
Lu YJ and Ren G: High frequency of the SDK1:AMACR fusion transcript
in Chinese prostate cancer. Int J Clin Exp Med. 8:15127–15136.
2015.PubMed/NCBI
|
|
30
|
Edwards SM, Kote-Jarai Z, Meitz J, Hamoudi
R, Hope Q, Osin P, Jackson R, Southgate C, Singh R, Falconer A, et
al: Two percent of men with early-onset prostate cancer harbor
germline mutations in the BRCA2 gene. Am J Hum Genet. 72:1–12.
2003. View
Article : Google Scholar : PubMed/NCBI
|
|
31
|
Mitra A, Fisher C, Foster CS, Jameson C,
Barbachanno Y, Bartlett J, Bancroft E, Doherty R, Kote-Jarai Z,
Peock S, Easton D; IMPACTEMBRACE, ; et al: Prostate cancer in male
BRCA1 and BRCA2 mutation carriers has a more aggressive phenotype.
Br J Cancer. 98:502–507. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Cui M, Gao XS, Gu X, Guo W, Li X, Ma M,
Qin S, Qi X, Xie M, Peng C and Bai Y: BRCA2 mutations should be
screened early and routinely as markers of poor prognosis: Evidence
from 8,988 patients with prostate cancer. Oncotarget.
8:40222–40232. 2017.PubMed/NCBI
|
|
33
|
Abate-Shen C, Shen MM and Gelmann E:
Integrating differentiation and cancer: The Nkx3.1 homeobox
gene in prostate organogenesis and carcinogenesis. Differentiation.
76:717–727. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Dutta A, Magnen C, Mitrofanova A, Ouyang
X, Califano A and Abate-Shen C: Identification of an NKX3.1-G9a-UTY
transcriptional regulatory network that controls prostate
differentiation. Science. 352:1576–1580. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Talos F, Mitrofanova A, Bergren SK,
Califano A and Shen MM: A computational systems approach identifies
synergistic specification genes that facilitate lineage conversion
to prostate tissue. Nat Commun. 8:146622017. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Ruiz M, Troncoso P, Bruns C and Bar-Eli M:
Activator protein 2alpha transcription factor expression is
associated with luminal differentiation and is lost in prostate
cancer. Clin Cancer Res. 7:4086–4095. 2001.PubMed/NCBI
|
|
37
|
Ruiz M, Pettaway C, Song R, Stoeltzing O,
Ellis L and Bar-Eli M: Activator protein 2alpha inhibits
tumorigenicity and represses vascular endothelial growth factor
transcription in prostate cancer cells. Cancer Res. 64:631–638.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Jonckheere N, Fauquette V, Stechly L,
Saint-Laurent N, Aubert S, Susini C, Huet G, Porchet N, Van
Seuningen I and Pigny P: Tumour growth and resistance to
gemcitabine of pancreatic cancer cells are decreased by AP-2alpha
overexpression. Br J Cancer. 101:637–644. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Aykut B, Ochs M, Radhakrishnan P, Brill A,
Höcker H, Schwarz S, Weissinger D, Kehm R, Kulu Y, Ulrich A and
Schneider M: EMX2 gene expression predicts liver metastasis
and survival in colorectal cancer. BMC Cancer. 17:5552017.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Giroux Leprieur E, Hirata T, Mo M, Chen Z,
Okamoto J, Clement G, Li H, Wislez M, Jablons DM and He B: The
homeobox gene EMX2 is a prognostic and predictive marker in
malignant pleural mesothelioma. Lung Cancer. 85:465–471. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Okamoto J, Hirata T, Chen Z, Zhou HM,
Mikami I, Li H, Yagui-Beltran A, Johansson M, Coussens LM, Clement
G, et al: EMX2 is epigenetically silenced and suppresses growth in
human lung cancer. Oncogene. 29:5969–5975. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Giri VN, Knudsen KE, Kelly WK, Abida W,
Andriole GL, Bangma CH, Bekelman JE, Benson MC, Blanco A, Burnett
A, et al: Roel of genetic testing for inherited prostate cancer
risk: Philadelphia prostate cancer consensus conference2017. J Clin
Oncol. 36:414–424. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Momozawa Y, Iwasaki Y, Hirata M, Liu X,
Kamatani Y, Takahashi A, Sugano K, Yoshida T, Murakami Y, Matuda K,
et al: Germline pathogenic variants in 7636 japanese patients with
prostate cancer and 12366 controls. J Natl Cancer Inst. Jun
19–2019.(Epub ahead of print). View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Venkitaraman AR: Cancer susceptibility and
the functions of BRCA1 and BRCA2. Cell. 108:171–182.
2002. View Article : Google Scholar : PubMed/NCBI
|
